De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Nevro Toekomstige groei
Future criteriumcontroles 0/6
Nevro zal naar verwachting groeien in winst en omzet met respectievelijk 7.9% en 2.9% per jaar. De winst per aandeel zal naar verwachting groeien met 9.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -46.8% zijn.
Belangrijke informatie
7.9%
Groei van de winst
9.1%
Groei van de winst per aandeel
Medical Equipment winstgroei | 17.5% |
Inkomstengroei | 2.9% |
Toekomstig rendement op eigen vermogen | -46.8% |
Dekking van analisten | Good |
Laatst bijgewerkt | 01 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding
Aug 11Nevro: Not Having My Back
Aug 09Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Jul 16Nevro Corp. (NYSE:NVRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
May 01Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Feb 25There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding
Jan 08Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Nov 16Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold
Sep 01Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?
Jul 10Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings
Feb 28Nevro falls to 52-week low; down ~49% over last year
Feb 22Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains
Feb 14Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Jan 13Nevro: Opportunity Overshadowed By Weaknesses
Dec 07Boston Scientific drives rival Nevro lower after remarks on neuromodulation
Oct 26Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval
Oct 13Nevro gets FDA approval for Costa Rica manufacturing operations
Oct 04Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Oct 02Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation
Sep 07Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Jun 17Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery
Jun 10Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 433 | -77 | -43 | -28 | 10 |
12/31/2025 | 412 | -96 | -52 | -37 | 15 |
12/31/2024 | 402 | -99 | -41 | -27 | 16 |
6/30/2024 | 426 | -77 | -65 | -56 | N/A |
3/31/2024 | 431 | -83 | -71 | -62 | N/A |
12/31/2023 | 425 | -92 | -67 | -59 | N/A |
9/30/2023 | 423 | -102 | -72 | -63 | N/A |
6/30/2023 | 419 | 3 | 13 | 22 | N/A |
3/31/2023 | 415 | 2 | 15 | 24 | N/A |
12/31/2022 | 406 | 3 | 17 | 25 | N/A |
9/30/2022 | 395 | -8 | 16 | 23 | N/A |
6/30/2022 | 388 | -140 | -80 | -72 | N/A |
3/31/2022 | 386 | -136 | -75 | -63 | N/A |
12/31/2021 | 387 | -131 | -54 | -42 | N/A |
9/30/2021 | 394 | -108 | -28 | -15 | N/A |
6/30/2021 | 409 | -68 | 1 | 12 | N/A |
3/31/2021 | 363 | -88 | -8 | 0 | N/A |
12/31/2020 | 362 | -83 | -5 | 1 | N/A |
9/30/2020 | 367 | -90 | -29 | -24 | N/A |
6/30/2020 | 358 | -98 | -43 | -39 | N/A |
3/31/2020 | 396 | -84 | -37 | -34 | N/A |
12/31/2019 | 390 | -104 | -54 | -50 | N/A |
9/30/2019 | 384 | -100 | -34 | -32 | N/A |
6/30/2019 | 379 | -93 | -37 | -34 | N/A |
3/31/2019 | 382 | -76 | -25 | -21 | N/A |
12/31/2018 | 387 | -49 | -14 | -6 | N/A |
9/30/2018 | 377 | -44 | -23 | -13 | N/A |
6/30/2018 | 364 | -39 | -11 | -2 | N/A |
3/31/2018 | 346 | -40 | N/A | -7 | N/A |
12/31/2017 | 327 | -37 | N/A | -14 | N/A |
9/30/2017 | 299 | -42 | N/A | -27 | N/A |
6/30/2017 | 278 | -40 | N/A | -35 | N/A |
3/31/2017 | 255 | -37 | N/A | -42 | N/A |
12/31/2016 | 229 | -32 | N/A | -59 | N/A |
9/30/2016 | 191 | -36 | N/A | -73 | N/A |
6/30/2016 | 146 | -52 | N/A | -101 | N/A |
3/31/2016 | 102 | -63 | N/A | -114 | N/A |
12/31/2015 | 70 | -67 | N/A | -100 | N/A |
9/30/2015 | 46 | -62 | N/A | -79 | N/A |
6/30/2015 | 39 | -50 | N/A | -57 | N/A |
3/31/2015 | 36 | -38 | N/A | -40 | N/A |
12/31/2014 | 33 | -31 | N/A | -31 | N/A |
9/30/2014 | 29 | -29 | N/A | -27 | N/A |
6/30/2014 | 27 | -26 | N/A | -24 | N/A |
3/31/2014 | 25 | -26 | N/A | -22 | N/A |
12/31/2013 | 24 | -26 | N/A | -21 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat NVRO de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat NVRO de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat NVRO de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van NVRO ( 2.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van NVRO ( 2.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat NVRO binnen 3 jaar verliesgevend zal zijn.